

Executive Corridor
Darlington Memorial Hospital
Hollyhurst Road
Darlington
DL3 6HX
Switchboard Tel: 01325 38 0100
Foundation Trust Office: 01325 74 3625
Corporate Records Office: 01325 74 3700

Request for Information Reference: 06.23.43

FOI Direct line: 01325 743700
Email: cdda-tr.cddftfoi@nhs.net

Email only

10th July 2023

Dear

Freedom of Information Act 2000 – Request for Information

Thank you for submitting a request for information which we received on 15th June 2023 in relation to County Durham and Darlington NHS Foundation Trust (the Trust). Your request has been processed under the provisions of the Freedom of Information Act 2000 and I am now able to provide you with a response.

Your request was in relation to Lung Cancer and I am providing the following information in response to your specific questions:

1. How many patients has your Trust treated in the past 3 months for:

These are treatments with a start date between 01/03/2023 and 31/05/2023.

Non-small cell lung cancer (NSCLC) - any treatment	49 (includes Palliative Care from Q2)
Non-small cell lung cancer (NSCLC) - surgical treatment	0
Non-small cell lung cancer (NSCLC) - radiotherapy	0
Non-small cell lung cancer (NSCLC) - systemic anti-cancer treatment (SACT)	125

2. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

AFATINIB	2
ALECTINIB	4
ATEZOLIZUMAB	13
ATEZOLIZUMAB + BEVACIZIMAB + CARBOPLATIN + PACLITAXEL	2
BRIGANTINIB	2
CARBOPLATIN + VINORELBINE	1
CARBOPLATIN + VINOURELBINE	1
CRIZOTINIB	1
DACOMITINIB	2
DENOSUMAB	9
DOCETAXEL	1
DURVALUMAB	10
GEMCITABINE + CARBOPLATIN	7
LORLATINIB	1
MOBOCERTINIB	1
OSIMERTINIB	9
PEMBROLIZUMAB	28
PEMBROLIZUMAB + CARBOPLATIN	8
PEMBROLIZUMAB + CARBOPLATIN + PACLITAXEL	2
PEMBROLIZUMAB + PEMETREXED	1
PEMBROLIZUMAB + PEMETREXED + CARBOPLATIN	2
SOTORASIB	2
TEPOTINIB	2
ZOLEDRONIC ACID	3
Other active systemic anti-cancer therapy [please state] Palliative care only	32

3. Of the NSCLC patients treated with Nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with Nivolumab?

Nil.

In line with the Information Commissioner's directive on the disclosure of information under the Freedom of Information Act 2000 your request will form part of our disclosure log on the Trust's website. However please be assured that we anonymise all responses prior to adding them to the disclosure log.

I hope that this response has provided you with the information you had requested. If you have any queries or wish to discuss the information supplied, please do not hesitate to contact me by telephone or in writing. If however, you are dissatisfied with the way in which your request has been handled and would like an internal review, you will need to contact me in writing at the above address or via cdda-tr.cddftfoi@nhs.

If you remain dissatisfied with our response following an internal review you have the right to appeal to The Information Commissioner at Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. More information is available on their website; www.ico.gov.uk.

Yours sincerely

Corporate Records and Freedom of Information Facilitator